- Home
- CURI vs ACIU Comparison
CURI vs ACIU Comparison
Compare CURI & ACIU Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CURI
- ACIU
- Stock Information
- Founded
- CURI N/A
- ACIU 2003
- Country
- CURI United States
- ACIU Switzerland
- Employees
- CURI N/A
- ACIU N/A
- Industry
- CURI Movies/Entertainment
- ACIU Biotechnology: Pharmaceutical Preparations
- Sector
- CURI Consumer Discretionary
- ACIU Health Care
- Exchange
- CURI Nasdaq
- ACIU Nasdaq
- Market Cap
- CURI 264.7M
- ACIU 213.3M
- IPO Year
- CURI N/A
- ACIU 2016
- Fundamental
- Price
- CURI $5.19
- ACIU $3.54
- Analyst Decision
- CURI Strong Buy
- ACIU Strong Buy
- Analyst Count
- CURI 3
- ACIU 2
- Target Price
- CURI $6.00
- ACIU $10.00
- AVG Volume (30 Days)
- CURI 513.8K
- ACIU 235.3K
- Earning Date
- CURI 11-05-2025
- ACIU 11-04-2025
- Dividend Yield
- CURI 6.14%
- ACIU N/A
- EPS Growth
- CURI N/A
- ACIU N/A
- EPS
- CURI N/A
- ACIU N/A
- Revenue
- CURI $60,840,000.00
- ACIU $36,362,036.00
- Revenue This Year
- CURI $34.86
- ACIU N/A
- Revenue Next Year
- CURI $9.69
- ACIU $1,022.98
- P/E Ratio
- CURI N/A
- ACIU N/A
- Revenue Growth
- CURI 11.02
- ACIU 86.71
- 52 Week Low
- CURI $1.47
- ACIU $1.43
- 52 Week High
- CURI $7.15
- ACIU $3.99
- Technical
- Relative Strength Index (RSI)
- CURI 59.08
- ACIU 67.64
- Support Level
- CURI $4.95
- ACIU $2.70
- Resistance Level
- CURI $5.34
- ACIU $3.99
- Average True Range (ATR)
- CURI 0.27
- ACIU 0.29
- MACD
- CURI -0.01
- ACIU 0.10
- Stochastic Oscillator
- CURI 64.04
- ACIU 72.56
About CURI CuriosityStream Inc.
CuriosityStream Inc is a media and entertainment company. It offers premium video programming across the principal categories of factual entertainment, including science, history, society, nature, lifestyle, and technology. Its mission is to provide premium real entertainment that informs, enchants, and inspires. Its product and services are Direct to Consumer Business, Partner Direct Business, Bundled Distribution, Content Licensing, Enterprise Subscriptions and Others. The majority of the revenue comes from the Direct to direct-to-consumer business.
About ACIU AC Immune SA
AC Immune SA is a clinical-stage biopharmaceutical company that focuses on neurodegenerative diseases. The company uses its proprietary technology platforms to discover, design, and develop novel proprietary small molecules, antibodies, and vaccines for the prevention, diagnosis, and treatment of neurodegenerative diseases associated with protein misfolding. The Company has one segment. The Company currently focuses mostly of its resources on discovering and developing therapeutic and diagnostic products targeting misfolded proteins. The company's pipeline consists of ACI-24.060, Crenezumab, ACI-35.030, Semorinemab, ACI-7104.056, and others.